

Supplementary Material
**Treatment Patterns and Treatment Satisfaction among Adults with Alopecia
Areata in the United States**

Authors

Moshe Fridman¹
Markqayne Ray²
Kavita Gandhi²
Morgan Shy¹
Arash Mostaghimi³

¹AMF Consulting, Los Angeles, CA 90036, United States

²Pfizer Inc, Collegeville, PA 19426, United States

³Brigham & Women's Hospital, Harvard University, Boston, MA 02115, United States

Corresponding Author: Moshe Fridman, PhD
AMF Consulting, Inc
846 S. Citrus Avenue
Los Angeles, CA 90036
Email: fmoshe@amf-consulting.com

Supplemental Table 1. Treatment switches from prior to current therapy

Prior Therapy	To Current Therapy:	From Prior Therapy:	Current Therapy
1. Oral corticosteroids, 6 (4%)	7. Combo corticosteroids, 5 (83%) 8. Combo with or solo immunomodulator, 1 (17%)	4. Topical immunotherapy, 1 (10%) 7. Combo corticosteroids, 2 (20%) 9. No prior therapy, 7 (70%)	1. Oral corticosteroids, 10 (2%)
2. Injectable corticosteroids, 22 (14%)	0. Not currently prescribed, 2 (9%) 3. Topical corticosteroids/TCI, 3 (14%) 5. Other, 4 (18%) 7. Combo corticosteroids, 8 (36%) 8. Combo with or solo immunomodulator, 5 (23%)	3. Topical corticosteroids/TCI, 10 (11%) 4. Topical immunotherapy, 2 (2%) 5. Other, 1 (1%) 7. Combo corticosteroids, 10 (11%) 8. Combo with or solo immunomodulator, 1 (1%) 9. No prior therapy, 66 (73%)	2. Injectable corticosteroids, 90 (21%)
3. Topical corticosteroids/TCI, 30 (19%)	0. Not currently prescribed, 1 (3%) 2. Injectable corticosteroids, 10 (33%) 3. Topical corticosteroids/TCI, 1 (3%) 5. Other, 1 (3%) 7. Combo corticosteroids, 12 (40%) 8. Combo with or solo immunomodulator, 5 (17%)	2. Injectable corticosteroids, 3 (6%) 3. Topical corticosteroids/TCI, 1 (2%) 5. Other, 4 (8%) 7. Combo corticosteroids, 5 (10%) 9. No prior therapy, 37 (74%)	3. Topical corticosteroids/TCI, 50 (11%)
4. Topical immunotherapy, 6 (4%)	1. Oral corticosteroids, 1 (17%) 2. Injectable corticosteroids, 2 (33%) 7. Combo corticosteroids, 1 (17%) 8. Combo with or solo immunomodulator, 2 (33%)	7. Combo corticosteroids, 1 (50%) 8. Combo with or solo immunomodulator, 1 (50%)	4. Topical immunotherapy, 2 (1%)
5. Other, 13 (8%)	0. Not currently prescribed, 1 (8%) 2. Injectable corticosteroids, 1 (8%) 3. Topical corticosteroids/TCI, 4 (31%) 7. Combo corticosteroids, 7 (54%)	2. Injectable corticosteroids, 4 (13%) 3. Topical corticosteroids/TCI, 1 (3%) 7. Combo corticosteroids, 5 (16%) 9. No prior therapy, 21 (68%)	5. Other, 31 (7%)
6. Combo immunotherapy, 0 (0%)		9. No prior therapy, 1 (100%)	6. Combo immunotherapy, 1 (0%)

7. Combo corticosteroids, 74 (48%)	0. Not currently prescribed, 9 (12%) 1. Oral corticosteroids, 2 (3%) 2. Injectable corticosteroids, 10 (14%) 3. Topical corticosteroids/TCI, 5 (7%) 4. Topical immunotherapy, 1 (1%) 5. Other, 5 (7%) 7. Combo corticosteroids, 32 (43%) 8. Combo with or solo immunomodulator, 10 (14%)	1. Oral corticosteroids, 5 (3%) 2. Injectable corticosteroids, 8 (4%) 3. Topical corticosteroids/TCI, 12 (6%) 4. Topical immunotherapy, 1 (1%) 5. Other, 7 (4%) 7. Combo corticosteroids, 32 (16%) 9. No prior therapy, 134 (67%)	7. Combo corticosteroids, 199 (45%)
8. Combo with or solo immunomodulator, 3 (2%)	2. Injectable corticosteroids, 1 (33%) 4. Topical immunotherapy, 1 (33%) 8. Combo with or solo immunomodulator, 1 (33%)	1. Oral corticosteroids, 1 (2%) 2. Injectable corticosteroids, 5 (12%) 3. Topical corticosteroids/TCI, 5 (12%) 4. Topical immunotherapy, 2 (5%) 7. Combo corticosteroids, 10 (24%) 8. Combo with or solo immunomodulator, 1 (2%) 9. No prior therapy, 18 (43%)	8. Combo with or solo immunomodulator, 42 (10%)
9. No prior therapy, 285	0. Not currently prescribed, 1 (0%) 1. Oral corticosteroids, 7 (2%) 2. Injectable corticosteroids, 66 (23%) 3. Topical corticosteroids/TCI, 37 (13%) 5. Other, 21 (7%) 6. Combo immunotherapy, 1 (0%) 7. Combo corticosteroids, 134 (47%) 8. Combo with or solo immunomodulator, 18 (6%)	2. Injectable corticosteroids, 2 (14%) 3. Topical corticosteroids/TCI, 1 (7%) 5. Other, 1 (7%) 7. Combo corticosteroids, 9 (64%) 9. No prior therapy, 1 (7%)	0. Not currently prescribed, 14 (3%)

Percent on colored bars represent the distribution of patients across treatment groups. Patients with no prior therapy were excluded from the prior therapy denominator as the category was added only to represent patients with no prior treatment.

Percent in 'to' and 'from' bars represent the distributions of switch to and from within each treatment group.

Total percent may not add up to 100% due to rounding.